Advertisement

Topics

Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run

11:17 EDT 29 Jun 2017 | Topix

This report highlights a trio of gene therapy names with additional upside for investors with an 18-month time horizon. BLUE should net at least $150,000 per patient with demand from thousands of patients annually by 2020-2022.

Original Article: Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run

NEXT ARTICLE

More From BioPortfolio on "Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run"

Advertisement
Quick Search
Advertisement
Advertisement